Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2012

Open Access 01-12-2012 | Research

Chemotherapy and skin reactions

Authors: Gabriella Fabbrocini, Norma Cameli, Maria Concetta Romano, Maria Mariano, Luigia Panariello, Dario Bianca, Giuseppe Monfrecola

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Login to get access

Abstract

Background

New chemotherapic agents and new protocols in oncology have led to an increasing survival rate in patients affected by tumors. However, this increased use has been accompanied by a growth in the incidence of cutaneous side effects and a worsening of patients’ quality of life. Appropriate management of skin toxicity associated with chemotherapic agents is therefore necessary for suitable drug administration and to improve quality of life and clinical outcomes.

Methods

We have clinically examined 100 patients affected by cancer, determining type, frequency, treatment, and evolution of side effects related to chemotherapy.

Results

The prevalent cutaneous side effects in patients undergoing chemotherapy are skin rash, xerosis, pruritus, paronychia, hair abnormality, and mucositis. The clinical cases are reported in detail.

Conclusion

Oncological therapies have become more selective and have low systemic toxicity because of their high specificity, but cutaneous side effects are common and may worsen the quality of life of these patients.
Appendix
Available only for authorised users
Literature
1.
Noushin H, Haley N, Susan B: Chemiotheraputic agents and the skin: an update. J Am Acad Dermatol. 2008, 58: 545-570. 10.1016/j.jaad.2008.01.001.CrossRef
2.
Tianhong L, Roman P: Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol. 2009, 4: 107-119. 10.1007/s11523-009-0114-0.CrossRef
3.
Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerkb J, Gelderblomb H: Classification and management of skin, hair and nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007, 43: 845-851. 10.1016/j.ejca.2006.11.016.CrossRefPubMed
4.
Jatoi A, Nguyen PL: Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist. 2008, 13: 1201-1204. 10.1634/theoncologist.2008-0149.CrossRefPubMed
5.
Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007, 21: 34-36.
6.
U. S. Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 4.03.2010
7.
Lacouture ME: The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park). 2009, 23: 194-196.
8.
Pérez-Soler R: Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology (Williston Park). 2003, 17: 23-28.
9.
Vasquez-Bayo C, Rodriguez-Bujaldon AL, Jimenez-Puya R, Galàn-Gutierrez M, Moreno-Gimenez JC: Capecitabine induced hyperpigmentation. Actas Dermosifiliogr. 2007, 98: 491-493. 10.1016/S0001-7310(07)70114-X.CrossRef
10.
Milano G, Etlenne-Grimaldi MC, Marl M, Lasalle S, Formento JL, Francoual M, et al: Candidate mechanisms for capecitabine related hand-foot syndrome. Br J Clin Pharmacol. 2008, 66: 188-95.CrossRef
11.
Dave S, Thappa DM: Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dermatol Online J. 2003, 9 (3): 14-PubMed
12.
Kumar S, Dixit R, Karmakar S, Paul S: Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Indian J Pharmacol. August, 42 (4): 243-244.CrossRef
13.
Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al: Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with Sorafenib. The Oncologist. 2010, 15: 85-92. 10.1634/theoncologist.2009-0143.PubMedCentralCrossRefPubMed
14.
Williams V, Cohen P, Stewart D: Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol. 2011, 50 (4): 396-402. 10.1111/j.1365-4632.2010.04822.x.CrossRefPubMed
15.
Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al: Hypertension and hand-foot skin reaction related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010, 29: 95-10.1186/1756-9966-29-95.PubMedCentralCrossRefPubMed
Metadata
Title
Chemotherapy and skin reactions
Authors
Gabriella Fabbrocini
Norma Cameli
Maria Concetta Romano
Maria Mariano
Luigia Panariello
Dario Bianca
Giuseppe Monfrecola
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-31-50

Other articles of this Issue 1/2012

Journal of Experimental & Clinical Cancer Research 1/2012 Go to the issue

Research

The cost of unresectable stage III or stage IV melanoma in Italy

Review

Therapeutic strategies in epithelial ovarian cancer

Research

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells

Research

Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines

Research

The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells

Research

Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits